214 related articles for article (PubMed ID: 38374618)
1. A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study.
Serhan M; Psihogios A; Kabir N; Bota AB; Mithani SS; Smith DP; Zhu DT; Greyson D; Wilson S; Fell D; Top KA; Bettinger JA; Wilson K
Hum Vaccin Immunother; 2024 Dec; 20(1):2293550. PubMed ID: 38374618
[TBL] [Abstract][Full Text] [Related]
2. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study.
Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K
Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021.
Glover C; Deng L; Larter C; Brogan C; Richardson O; Huang YA; Kay E; Macartney K; Wood N
Commun Dis Intell (2018); 2024 Jun; 48():. PubMed ID: 38926650
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events following Immunization with COVID-19 Vaccines: A Narrative Review.
Bhandari B; Rayamajhi G; Lamichhane P; Shenoy AK
Biomed Res Int; 2022; 2022():2911333. PubMed ID: 36017393
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
[TBL] [Abstract][Full Text] [Related]
7. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
8. Participant-centred active surveillance of adverse events following immunisation: a narrative review.
Cashman P; Macartney K; Khandaker G; King C; Gold M; Durrheim DN
Int Health; 2017 May; 9(3):164-176. PubMed ID: 28582563
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.
Guo B; Page A; Wang H; Taylor R; McIntyre P
Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with intention for revaccination among patients with adverse events following immunization.
Muñoz CE; Pham-Huy A; Pernica JM; Boucher FD; De Serres G; Vaudry W; Constantinescu C; Sadarangani M; Bettinger JA; Tapiéro B; Morris SK; McConnell A; Noya F; Halperin SA; Top KA;
Vaccine; 2023 Oct; 41(42):6239-6247. PubMed ID: 37666696
[TBL] [Abstract][Full Text] [Related]
11. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.
Lei J; Balakrishnan MR; Gidudu JF; Zuber PLF
Vaccine; 2018 Mar; 36(12):1577-1582. PubMed ID: 29454518
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia.
Supangat ; Sakinah EN; Nugraha MY; Qodar TS; Mulyono BW; Tohari AI
BMC Pharmacol Toxicol; 2021 Oct; 22(1):58. PubMed ID: 34641944
[TBL] [Abstract][Full Text] [Related]
13. Adverse events following immunization of COVID-19 vaccine among children aged 6-11 years.
Puspitarani F; Sitaresmi MN; Ahmad RA
Front Public Health; 2022; 10():999354. PubMed ID: 36388348
[TBL] [Abstract][Full Text] [Related]
14. Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya.
Amdany H; Koech B
JBI Evid Implement; 2023 Jun; 21(2):146-155. PubMed ID: 36545897
[TBL] [Abstract][Full Text] [Related]
15. Comparison of adverse effects following immunisation degree after the administration COVID-19 vaccine of different platforms.
Bermawi B; Donastin A; Sari NDK; Kurniasari DW; Adriansyah AA; Ferdiansyah MA; Rofananda IF; Surya PA
Med J Malaysia; 2024 Mar; 79(2):124-127. PubMed ID: 38553914
[TBL] [Abstract][Full Text] [Related]
16. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance.
Hagos AA; Sahile Z; Ahmed W; Phanouvong S
Glob Health Sci Pract; 2024 Feb; 12(Suppl 1):. PubMed ID: 38216210
[TBL] [Abstract][Full Text] [Related]
17. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India.
Joshi J; Das MK; Polpakara D; Aneja S; Agarwal M; Arora NK
Indian J Pediatr; 2018 Feb; 85(2):139-148. PubMed ID: 29170922
[TBL] [Abstract][Full Text] [Related]
18. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
Front Immunol; 2022; 13():965171. PubMed ID: 36263025
[TBL] [Abstract][Full Text] [Related]
19. Implementation of data triangulation and dashboard development for COVID-19 vaccine adverse event following immunisation (AEFI) data in Nigeria.
Shragai T; Adegoke OJ; Ikwe H; Sorungbe T; Haruna A; Williams I; Okonkwo R; Onu K; Asekun A; Gberikon M; Iwara E; Abimiku A; Rufai A; Okposen B; Gidudu J; Lam E; Bolu O
BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650016
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.
Gold MS; Lincoln G; Cashman P; Braunack-Mayer A; Stocks N
Vaccine; 2021 Jan; 39(2):332-342. PubMed ID: 33279317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
